Related Experiment Video
Updated: Oct 12, 2025
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
Xuning Wang1,2, Shixiang Wang3, Yalin Han1,4
1The Air Force Hospital of Northern Theater PLA, Shenyang, People's Republic of China.
Background:
Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed.
Methods:
Public sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy.
Results:
We found that CSMD1 is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens.
Conclusion:
CSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.
Insights
CSMD1 gene mutations may predict gastric cancer patient response to immunotherapy. This finding could improve patient selection for immune checkpoint therapy, enhancing treatment effectiveness.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Immunotherapy, including immune checkpoint therapy (ICT), shows promise for gastric cancer (GC) treatment.
- Accurate patient selection for ICT remains a challenge.
- Biomarkers are needed to identify GC patients likely to benefit from immunotherapy.
Purpose of the Study:
- To identify potential biomarkers for predicting immunotherapy response in gastric cancer.
- To explore the correlation between gene mutations and patient prognosis and immune profiles.
Main Methods:
- Analysis of public sequence and clinical data from gastric cancer patients.
- Investigating the mutation status of genes and their association with clinical outcomes and immune markers.
Main Results:
- CSMD1 was the most frequently mutated gene in gastric cancer.
- CSMD1 mutations correlated with improved prognosis, higher tumor mutation burden, and increased PD-L1 expression.
- Patients with CSMD1 mutations showed higher microsatellite instability (MSI), more activated CD4+ T cells, and increased neoantigens.
Conclusions:
- CSMD1 mutation may serve as a novel biomarker for predicting survival in gastric cancer.
- CSMD1 mutation status could guide patient selection for immune checkpoint therapy in gastric cancer.
Related Concept Videos
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
02:23Abnormal Proliferation